Filing Context and Reporting Period
The provided Form 10-Q is for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc.; investors should verify the company identity before relying on this summary. The filing covers the quarter and six months ended June 30, 2023, with unaudited consolidated financial statements. Selecta is a clinical-stage biotechnology company developing tolerogenic therapies based on its ImmTOR platform. It had no approved products or product revenue.
Financial Performance and Position
| Metric | Three months ended June 30, 2023 | Three months ended June 30, 2022 | Six months ended June 30, 2023 | Six months ended June 30, 2022 |
|---|---|---|---|---|
| Collaboration and license revenue | $5.2 million | $39.3 million | $11.2 million | $73.3 million |
| Research and development expense | $17.8 million | $19.2 million | $36.4 million | $36.9 million |
| General and administrative expense | $6.1 million | $6.2 million | $11.8 million | $11.8 million |
| Operating income (loss) | $(18.6) million | $13.9 million | $(37.0) million | $24.6 million |
| Net income (loss) | $(11.4) million | $8.6 million | $(33.1) million | $37.4 million |
| Net income (loss) per diluted share | $(0.07) | $0.06 | $(0.22) | $0.17 |
- Approximate operating margins were (355)% for the quarter and (331)% for the six-month period. Approximate net margins were (217)% and (295)%, respectively.
- The quarter included $1.4 million of investment income and $6.3 million of income from a decrease in the fair value of warrant liabilities. The six-month period included $2.7 million of investment income and $2.3 million of warrant-liability revaluation income.
- Cash, cash equivalents and restricted cash totaled $115.0 million at June 30, 2023, including $3.0 million of restricted cash and $0.2 million held by the Russian subsidiary. Cash and cash equivalents were $112.0 million; no marketable securities remained at quarter-end.
- Net cash used in operating activities was $18.7 million for the six months, compared with $24.1 million in the prior-year period. Investing activities provided $28.1 million, principally from maturities of marketable securities, while financing activities used $2.4 million, primarily for debt repayments.
- Outstanding term-loan principal was $22.4 million at June 30, 2023, with $10.2 million classified as current and $13.8 million classified as non-current after debt discount. Future minimum principal payments total $22.4 million through 2025.
- Total liabilities were $74.1 million and stockholders’ equity was $65.4 million. Accumulated deficit was $428.0 million.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue declined 87%, and six-month revenue declined 85%, primarily because the prior-year periods included larger Sobi-related amounts, Sarepta revenue, and recognition of deferred revenue following termination of the Spark agreement.
- The company moved from net income of $8.6 million in the second quarter of 2022 to a net loss of $11.4 million in the second quarter of 2023. For the six-month period, results moved from net income of $37.4 million to a net loss of $33.1 million.
- Research and development expense decreased 7% year over year in the quarter and 1% for the six-month period, reflecting strategic reprioritization, partly offset by headcount-reduction charges and increased contract license and milestone payments.
- In April 2023, Selecta paused development of SEL-302 for methylmalonic acidemia and implemented a targeted headcount reduction of approximately 25%.
- In January 2023, Selecta entered into an Astellas agreement for Xork, receiving a $10.0 million upfront payment and becoming eligible for up to $340.0 million in additional milestone payments plus royalties. Revenue recognized under the agreement was $0.8 million for the quarter and $1.4 million year to date.
- Takeda notified Selecta in April 2023 that it intended to terminate its agreement effective July 25, 2023. Selecta recognized a $0.5 million Takeda milestone during the quarter.
- On August 17, 2023, after quarter-end, Selecta announced further prioritization of SEL-212 and the Astellas Xork collaboration, while pausing other clinical and preclinical programs it was no longer actively advancing.
Guidance, Outlook, Risks and Unusual Items
- Management stated that cash, cash equivalents and restricted cash at June 30, 2023 would fund current planned operations for at least the next twelve months. Following the strategic reprioritization, management separately estimated that available cash plus the next anticipated SEL-212 milestone could fund operations into 2027. These estimates are subject to substantial risks and may prove incorrect.
- Selecta expects continuing operating losses and does not expect product revenue for the foreseeable future. Additional financing, collaborations, milestone receipts, royalty or milestone monetization, debt, or equity issuance may be required; financing could be dilutive or unavailable on favorable terms.
- SEL-212 generated positive topline Phase 3 DISSOLVE I and II results in March 2023. The program is partnered with Sobi, which reimburses certain development costs. Regulatory approval and commercialization remain uncertain.
- The company had 31.2 million outstanding warrants, including 29.0 million liability-classified warrants, with a June 30 fair value of $16.9 million. Changes in the liability’s fair value can materially affect reported earnings without corresponding operating cash flow.
- The term loan is secured by substantially all assets other than intellectual property, while proceeds and rights related to intellectual-property transactions are included in the collateral package. Defaults could permit acceleration.
- As of June 30, 2023, the filing reported no material litigation, no material changes to previously disclosed risk factors, no off-balance-sheet arrangements, and effective disclosure controls.
Facts Investors Should Verify
- Issuer identity: Confirm whether the intended filing was Selecta Biosciences or Cartesian Therapeutics, because the supplied document names Selecta throughout.
- Verify the sustainability and timing of collaboration revenue, including Sobi reimbursements, Astellas payments, and the consequences of Takeda’s termination.
- Assess whether the stated cash runway through 2027 remains valid after incorporating operating losses, debt maturities, development obligations, and uncertain milestone receipts.
- Review the clinical, regulatory, and commercial prospects of SEL-212 and the remaining Xork obligations with Astellas.
- Evaluate potential dilution from 31.2 million warrants, approximately 20.1 million outstanding options, restricted stock units, and other reserved shares.
- Confirm the impact of the August 17, 2023 program reprioritization and any later corporate name, merger, or strategic changes not reflected in the quarter-end financial statements.